Type of Mesothelioma:
The prognostic value of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography parameters in patients with malignant pleural mesothelioma
Turk Gogus Kalp Damar Cerrahisi Derg 2021 January 13 [Link] Bülent Mustafa Yenigün, Yusuf Kahya, Çiğdem Soydal, Nihal Ata Tutkun, Gökhan Kocaman, Emre Muhammed Koçak, Elgin Özkan, Serpil Dizbay Sak, Ayten Kayı Cangır Abstract Background: In this study, we aimed to investigate the prognostic value of metabolic 18F-fluorodeoxyglucose positron emission tomography/computed tomography parameters in malignant…
Read MoreTreatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting
Future Oncology 2021 March 26 [Link] David M Waterhouse, Esmond D Nwokeji, Marley Boyd, John R Penrod, Janet L Espirito, Nicholas J Robert, Melinda J Daumont Abstract Aim: To assess real-world treatment patterns and outcomes among patients with advanced malignant pleural mesothelioma. Patients & methods: Retrospective database analysis. Results: In all, 469 patients received first-line…
Read MoreEfficacy of second-line treatment and prognostic factors in patients with advanced malignant peritoneal mesothelioma: a retrospective study
BMC Cancer 2021 March 20 [Link] Rui Kitadai, Tatsunori Shimoi, Kazuki Sudo, Emi Noguchi, Yusuke Nagata, Ryoichi Sawada, Atsuo Takashima, Narikazu Boku, Kan Yonemori Abstract Background: Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to malignant pleural mesothelioma. We previously reported the efficacy of cisplatin plus pemetrexed…
Read MoreClonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
Nature Communications 2021 March 19 [Link] Min Zhang, Jin-Li Luo, Qianqian Sun, James Harber, Alan G Dawson, Apostolos Nakas, Sara Busacca, Annabel J Sharkey, David Waller, Michael T Sheaff, Cathy Richards, Peter Wells-Jordan, Aarti Gaba, Charlotte Poile, Essa Y Baitei, Aleksandra Bzura, Joanna Dzialo, Maymun Jama, John Le Quesne, Amrita Bajaj, Luke Martison, Jacqui A…
Read MoreMetastasis of Sarcomatoid Malignant Mesothelioma With p16/CDKN2A Deletion Manifested as a Subcutaneous Mass in the Back: A Case Report and Review of Literature
International Journal of Surgical Pathology 2021 March 17 [Link] Kai-Bo Chen, Ya-Jing Huang, Yi Huang, Zhi-Wei Wu, Xiao-Li Jin, Hang Zhang, Xue-Ping Xiang, Lin Chen, Li Chen Abstract Sarcomatoid malignant mesothelioma (MM) is a rare and aggressive disease, and its diagnosis is challenging. A 60-year-old man presented with a recurrent subcutaneous mass in his right…
Read MoreAccuracy of pleural biopsy for the diagnosis of histologic subtype of malignant pleural mesothelioma: Necropsy-based study of 134 cases
Tumori 2021 March 15 [Link] Pietro Gino Barbieri, Dario Consonni, Manuela Schneider Abstract Background: Definition of histologic subtype of malignant pleural mesothelioma (MPM) is important for management of patients, because surgical treatment improves prognosis for patients with epithelioid but not biphasic or sarcomatoid MPM. In a series of necropsies performed in a hospital specialized for…
Read MoreThe expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma
Journal of Thoracic Disease 2021 February [Link] Camila M Baldavira, Juliana Machado-Rugolo, Tabatha G Prieto, Daniel R Bastos, Marcelo Balancin, Alexandre M Ab’Saber, Lygia B Yaegashi, Paola C Souza, Cecilia Farhat, Teresa Y Takagaki, Maria Ap Nagai, Vera L Capelozzi Abstract Background: Pleckstrin homology domain family A (PHLDA) genes play important roles in cancer cellular…
Read MoreUse of preclinical models for malignant pleural mesothelioma
Thorax 2021 March 10 [Link] Marie Shamseddin, Joanna Obacz, Mathew J Garnett, Robert Campbell Rintoul, Hayley Elizabeth Francies, Stefan John Marciniak Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer most commonly caused by prior exposure to asbestos. Median survival is 12-18 months, since surgery is ineffective and chemotherapy offers minimal benefit. Preclinical models that…
Read MoreOutcomes of multicystic peritoneal mesothelioma treatment with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
BJS Open 2021 March 5 [Link] A Zahid, L Clarke, N Carr, K Chandrakumaran, A Tzivanakis, S Dayal, F Mohamed, T Cecil, B J Moran Abstract Background: Multicystic peritoneal mesothelioma (MCPM) is a rare neoplasm, generally considered a borderline malignancy, best treated by cytoreductive surgery (CRS) to remove macroscopic disease, combined with hyperthermic intraperitoneal chemotherapy…
Read MoreProphylactic irradiation of tracts in patients with malignant pleural mesothelioma: A systematic review and meta-analysis of randomized trials
Critical Reviews in Oncology/Hematology 2021 March 3 [Link] Chia Ching Lee, Yu Yang Soon, Balamurugan Vellayappan, Cheng Nang Leong, Wee Yao Koh, Jeremy C S Tey Abstract Introduction: The role of prophylactic irradiation of tracts (PIT) to prevent tumor seeding at the site of a diagnostic or therapeutic intervention in patients with malignant pleural mesothelioma…
Read More